| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CFO & Chief Strategy Officer
1 company
Howard Liang last filed a Form 4 in June 2021, as CFO & Chief Strategy Officer at ONC. Howard Liang's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Howard Liang's trades have earned a middling insider score of 59/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +56.0%.
Howard Liang has 18 Form 4 filings on record from June 2017 to June 2021, all as CFO & Chief Strategy Officer at BeOne Medicines (ONC), 2017–2021.
The 76 reported transactions were 58 open-market sales, 11 option exercises, 4 option or other derivative awards and 3 stock awards.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $48.8M.
The largest open-market sale was 91,900 shares of ONC at an average $229.04 on December 14, 2020, about $21.0M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 28, 2021 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 446 | $365.00 | $162,790.00 | -100% | +5.4% | -53.9% | |
| Jun 18, 2021 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 486 | $325.89 | $158,383.46 | -100% | +19.7% | -58.9% | |
| Jun 7, 2021 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 650 | $354.16 | $230,202.50 | -100% | +0.7% | -55.1% | |
| Jan 15, 2021 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 14,000 | $344.85 | $4,827,945.23 | - | - | - | |
| Dec 14, 2020 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 91,900 | $229.04 | $21,048,454.15 | - | - | - | |
| Oct 5, 2020 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 14,000 | $299.60 | $4,194,413.48 | - | - | - | |
| Sep 14, 2020 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 14,000 | $250.27 | $3,503,763.52 | - | - | - | |
| Jun 29, 2020 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 300 | $191.23 | $57,368.01 | -100% | - | - | |
| Jun 8, 2020 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sell | 453 | $170.84 | $77,390.52 | -100% | - | - | |
| Nov 18, 2019 | ONC Beone Medicines Ltd. | CFO & Chief Strategy Officer | Sale+OE | 25,000 | $194.34 | $4,858,616.04 | - | - | - |